1,151 results on '"Vainchenker, W."'
Search Results
2. Distinct localizations and roles of non‐muscle myosin II during proplatelet formation and platelet release
3. Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms
4. The abnormal proplatelet formation in MYH9‐related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition
5. Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin
6. Developmental changes in human megakaryopoiesis
7. Thrombopoetin
8. Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation
9. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
10. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases
11. Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment
12. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma
13. Of men and mice: divergence effect of HDAC6 on proplatelet formation: OR082
14. Overexpression of the partially activated αIIbβ3D723H integrin salt bridge mutant downregulates RhoA activity and induces microtubule‐dependent proplatelet–like extensions in Chinese hamster ovary cells
15. Regulation of megakaryocyte maturation and platelet formation
16. Sustained Delivery of Erythropoietin in Mice by Genetically Modified Skin Fibroblasts
17. A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression
18. Myelofibrosis, JAK2 inhibitors and erythropoiesis
19. JAK/STAT signaling in hematological malignancies
20. JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
21. Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells
22. The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development
23. Mutations of ASXL1 gene in myeloproliferative neoplasms
24. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis
25. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
26. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage
27. Miscreant myeloproliferative disorder stem cells
28. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features
29. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition
30. In vitro and in vivo evaluation of the haematopoietic potential of skeletal muscle in a non-human primate model
31. p210BCR-ABL reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription
32. Oncogenic mechanisms in myeloproliferative disorders
33. Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators
34. From hematopoietic stem cells to platelets
35. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
36. Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases
37. The pediatric acute leukemia fusion oncogene ETO2-GLIS2 increases self-renewal and alters differentiation in a human induced pluripotent stem cells-derived model
38. A lentiviral vector encoding the human Wiskott–Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice
39. Membrane-bound Delta-4 Notch ligand reduces the proliferative activity of primitive human hematopoietic CD34+CD38low cells while maintaining their LTC-IC potential
40. Hemostasis and thrombosis in JAK2V617F-KI mice: PA 1.03–3
41. Hemostasis and thrombosis in JAK2V617F-KI mice: OC 58.5
42. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette
43. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7
44. Unfractionated peripheral blood stem cell autografts and CD34+-enriched autografts have similar long-term culture initiating capacity in multiple myeloma
45. Alterations of NFIA in chronic malignant myeloid diseases
46. Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells
47. Inhibition of erythroid differentiation and induction of megakaryocytic differentiation by thrombopoietin are regulated by two different mechanisms in TPO-dependent UT-7/c-mpl and TF-1/c-mpl cell lines
48. Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression
49. Frequent inactivating mutations of TET2 and CBL are associated with acquired uniparental disomy in atypical chronic myeloid leukemia: V99 - Best Abstract
50. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.